// App-Quantinova.ai

TPS8553 : Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).

Researchers

Presenter

  • Nizar J. Bahlis

Principal Investigators

  • Jeffrey A. Zonder

  • Susan Wroblewski

  • Ming Qi

  • Thomas Renaud

  • Carolyn Chang Jackson

  • Thierry Facon

Medical Centers

  • University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • University of Lille, CHU Lille, Service des Maladies du Sang,Lille,Frankreich

Locations

  • Canada

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • rHuPH20

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03871829

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved